PCDH17 Antibody, Biotin conjugated
Description
Introduction to PCDH17 Antibody, Biotin Conjugated
PCDH17 (Protocadherin 17) is a cell adhesion molecule involved in neuronal development and synaptic plasticity. The PCDH17 Antibody, Biotin conjugated is a specialized immunoreagent where a biotin molecule is covalently attached to the antibody, enabling high-affinity binding to streptavidin or avidin. This conjugation enhances signal detection in assays like ELISA, Western blot (WB), and immunohistochemistry (IHC), leveraging the biotin-avidin interaction for amplified sensitivity .
Structure and Conjugation Mechanism
The biotin-conjugated PCDH17 antibody retains the specificity of the original antibody while gaining versatility through biotinylation. Key features include:
The biotin moiety enables compatibility with streptavidin-conjugated enzymes (e.g., HRP, AP) or fluorophores, allowing flexible detection strategies .
ELISA and Signal Amplification
Biotin-conjugated PCDH17 antibodies are critical in ELISA protocols for quantifying PCDH17 levels. The biotin-streptavidin interaction amplifies signals, improving assay sensitivity. For example:
-
Detection Protocol: Biotinylated primary antibody binds PCDH17, followed by streptavidin-HRP conjugate addition. TMB substrate generates a colorimetric signal proportional to PCDH17 concentration .
-
Interference Considerations: High endogenous biotin levels in samples (e.g., freeze-dried egg yolks) may falsely elevate signals, necessitating blocking agents or alternative detection methods .
Immunohistochemistry (IHC)
In IHC, biotin-conjugated antibodies enable precise localization of PCDH17 in tissue sections. Streptavidin-linked markers (e.g., Alexa Fluor dyes) enhance fluorescence detection:
-
Example Workflow:
Western Blot (WB)
While less common for biotin-conjugated antibodies, WB applications leverage streptavidin-HRP for enhanced band detection:
-
Observed Bands: ~150–170 kDa in mouse/rat brain lysates and human tissues .
-
Dilution Recommendations: 1:500–1:1000 for unconjugated antibodies; biotin-conjugated variants may require optimization .
Advantages of Biotin Conjugation
Challenges and Mitigation Strategies
Product Overview
| Supplier | Catalog # | Conjugate | Applications | Quantity | Price |
|---|---|---|---|---|---|
| Bioss Inc. | - | Biotin | ELISA, IHC | 100 µl | $447.00 |
| Creative Biolabs | CBMOAB-91644FYA | Biotin | WB, ELISA | Inquire | Inquire |
Data sourced from Biocompare listings .
Key Considerations
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- Methylation of PCDH17 may play a significant role in the development and progression of high-grade serous ovarian carcinoma (HGSOC) and could potentially serve as a target for new clinical biomarkers. PMID: 29991130
- PCDH17 methylation in serum has been identified as a potential prognostic biomarker for patients with renal cell carcinoma after surgery. PMID: 28688232
- PCDH17 functions as a tumor suppressor, inhibiting Wnt/beta-catenin signaling and metastasis in breast cancer. However, frequent methylation of PCDH17 in primary tumors suggests its potential as a biomarker. PMID: 27351130
- Aberrant methylation of protocadherin 17 has been linked to acute lymphoblastic leukemia. PMID: 27643535
- PCDH-17 has been shown to inhibit metastasis through the EGFR/MEK/ERK signaling pathway. PMID: 26386721
- Combined methylation analysis of POU4F2/PCDH17 has demonstrated the highest sensitivity (90.00%) and specificity (93.96%) in detecting bladder cancer across diverse sample groups. This finding suggests the potential of this combination for effective bladder cancer detection. PMID: 26700620
- PCDH17 methylation in serum is a common occurrence in early-stage prostate cancer, and it is an independent predictor of biochemical recurrence (BCR) after radical prostatectomy. PMID: 26683656
- PCDH17 methylation has been observed more frequently in clear cell renal cell carcinoma patients and is associated with malignant clinicopathological characteristics and poor prognosis. PMID: 26404644
- PCDH17 promoter methylation has a strong association with bladder cancer malignancy and can be used as an independent predictor of clinical outcomes in patients with bladder cancer. PMID: 24567353
- PCDH17 promoter methylation has been shown to be significantly associated with malignant behavior and poor prognosis in bladder cancer patients. PMID: 24366498
- This study highlights the crucial role of PCDH17 in the synaptic development of specific corticobasal ganglia circuits and suggests its involvement in these circuits in depressive behaviors. PMID: 23684785
- PCDH17 acts as a tumor suppressor, inhibiting proliferation by inducing apoptosis and autophagy. It is frequently silenced in gastric and colorectal cancers. PMID: 22926751
- Research indicates that PCDH17 is transcriptionally downregulated in gastric cancer due to aberrant promoter CpG island methylation. PMID: 22207556
- Statistical analysis revealed significant downregulation of PCDH17/PCH68 and PTPRD. PMID: 21213369
- Findings suggest that silencing of PCDH17 expression through promoter hypermethylation or other mechanisms leads to the loss of its tumor-suppressive activity, potentially contributing to the development of a subgroup of ESCCs. PMID: 20200074
- Azoospermic testis exhibited down-regulation of CDH18 and PCDH17. PMID: 20180417
- The study discusses the occurrence of an unusual TG 3' splice site in intron 2. PMID: 17672918
